Saturday, November 7, 2026

BTC $75,828 ▼ 0.22%

NewsLive Wire Politics World Markets Digital Assets Technology Sports

FranchisesThe Brief The Big Read The Breakdown Crypto Culture

MoreDeFi & On-Chain U.S. Equities Macro & Rates Research

LIVE

BTC$75,828−0.22%ETH$2,240+0.17%SOL$89.70−0.53%XRP$1.16−2.31%LINK$10.79−0.84%ADA$0.182−2.13%S&P 5007,377+0.31%Nasdaq24,579+1.09%Dow51,286−0.46%RUT2,754+0.89%TNX4.86%+0.45%TYX5.26%+0.17%FVX4.65%+0.87%IRX4.00%+0.33%VIX25.64−9.01%GOLD$4,074.90−0.94%SILVER$51.94−0.83%OIL$90.83+0.34%DXY102.28−0.02%NVDA$186.64+2.78%AAPL$342.37−0.52%TSLA$358.22+4.23%META$610.15+0.84%MSFT$530.61−0.99%AMZN$259.30−0.35%GOOGL$284.78+0.78%Fear & Greed25 — Extreme FearBTC$75,828−0.22%ETH$2,240+0.17%SOL$89.70−0.53%XRP$1.16−2.31%LINK$10.79−0.84%ADA$0.182−2.13%S&P 5007,377+0.31%Nasdaq24,579+1.09%Dow51,286−0.46%RUT2,754+0.89%TNX4.86%+0.45%TYX5.26%+0.17%FVX4.65%+0.87%IRX4.00%+0.33%VIX25.64−9.01%GOLD$4,074.90−0.94%SILVER$51.94−0.83%OIL$90.83+0.34%DXY102.28−0.02%NVDA$186.64+2.78%AAPL$342.37−0.52%TSLA$358.22+4.23%META$610.15+0.84%MSFT$530.61−0.99%AMZN$259.30−0.35%GOOGL$284.78+0.78%Fear & Greed25 — Extreme Fear

Tag

ABBV

3 articles

U.S. Equities1h ago

AbbVie's Vraylar Heads for IRA Price Cut in 2027; Imbruvica Already Down 26 Percent

AbbVie warned investors to model lower prices for its $4.2 billion psychiatry drug Vraylar starting in 2027 under Medicare price negotiation, as its cancer drug Imbruvica faces a 26 percent sales cliff from IRA pricing.

U.S. Equities8d ago

AbbVie Raises FY Guidance on Skyrizi, Rinvoq Momentum

AbbVie beat Q3 EPS and revenue estimates, raising full-year adjusted EPS guidance to $13.95-$13.99 on strength in immunology franchises

U.S. Equities35d ago

AbbVie's Juvmo Approval Validates $8.7B Cerevel Bet, Eyes $1.4B Peak Sales

FDA approval of Juvmo, AbbVie's once-daily Parkinson's treatment, delivers near-term validation of its Cerevel acquisition and positions a new growth driver as Humira patent cliff deepens.